Aventis Pharma

Aventis Pharma's Net Profit Rose 17.2%

Aventis Pharma's Net Profit Rose 17.2%

Aventis Pharma surged around 8% during morning trade due to a strong influence from the announcement that it has agreed to acquire Universal Medicare's business of marketing and distribution of branded nutraceutical formulations in India.

The company has notified the move during the initial trading hours. Consequently, it has observed good buying support and the stock spurted by 7.92% to touch an early high of Rs 2,199.90 on the BSE. Simultaneously, the NSE has reflected a similar scenario where the stock zoomed up by 7.44 % to an early high of Rs 2,195.